| Literature DB >> 27879664 |
Xueqin Li1, Jun Shen2, Yunyao Jiang3,4, Ting Shen5,6, Long You7,8, Xiaobo Sun9, Xudong Xu10, Weicheng Hu11,12, Haifeng Wu13, Gongcheng Wang14.
Abstract
Chloranthalactone B (CTB), a lindenane-type sesquiterpenoid, was obtained from the Chinese medicinal herb Sarcandra glabra, which is frequently used as a remedy for inflammatory diseases. However, the anti-inflammatory mechanisms of CTB have not been fully elucidated. In this study, we investigated the molecular mechanisms underlying these effects in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. CTB strongly inhibited the production of nitric oxide and pro-inflammatory mediators such as prostaglandin E₂, tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and IL-6 in RAW264.7 cells stimulated with LPS. A reverse-transcription polymerase chain reaction assay and Western blot further confirmed that CTB inhibited the expression of inducible nitric oxide synthase, cyclooxygenase-2, TNF-α, and IL-1β at the transcriptional level, and decreased the luciferase activities of activator protein (AP)-1 reporter promoters. These data suggest that inhibition occurred at the transcriptional level. In addition, CTB blocked the activation of p38 mitogen-activated protein kinase (MAPK) but not c-Jun N-terminal kinase or extracellular signal-regulated kinase 1/2. Furthermore, CTB suppressed the phosphorylation of MKK3/6 by targeting the binding sites via formation of hydrogen bonds. Our findings clearly show that CTB inhibits the production of inflammatory mediators by inhibiting the AP-1 and p38 MAPK pathways. Therefore, CTB could potentially be used as an anti-inflammatory agent.Entities:
Keywords: Sarcandra glabra; chloranthalactone B; inflammation; sesquiterpene
Mesh:
Substances:
Year: 2016 PMID: 27879664 PMCID: PMC5133933 DOI: 10.3390/ijms17111938
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Chemical structure of chloranthalactone B (CTB).
Figure 2Effects of CTB on cell viability (A) and nitric oxide (NO) (B); prostaglandin E2 (PGE2) (C); tumor necrosis factor α (TNF-α) (D); interleukin-1β (IL-1β) (E); and IL-6 (F) production in RAW264.7 cells. (A) RAW264.7 cells were seeded in 96-well plates and treated with CTB at the indicated concentrations for 24 h. Cell proliferation was estimated by the 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay (A); RAW264.7 cells were seeded in 96-well plates and pre-treated with CTB for 30 min before the addition of 1 µg/mL LPS for 24 h. Supernatants were collected, and NO levels in culture media were determined using Griess assays (B); Levels of PGE2, TNF-α, IL-1β, and IL-6 in culture media were quantified using enzyme-linked immunosorbent assay (ELISA) kits (C–F). Values are the mean ± standard derivation (SD) of triplicate experiments. * p < 0.05 compared to LPS treatment alone; # p < 0.05 compared to control group.
Figure 3Effects of CTB on inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor α (TNF-α), and interleukin-1β (IL-1β) expression in LPS-treated RAW264.7 cells. RAW264.7 cells were pre-treated with different concentrations of CTB (25, 50 µM) for 30 min before treatment with 1 µg/mL LPS for 6 h. iNOS, TNF-α, COX-2, and IL-1β mRNA expression was measured by semi-quantitative PCR (A) and real-time PCR (B); iNOS, TNF-α, COX-2, and IL-1β protein expression was measured by western blot (C). A typical experiment from three independent experiments is shown. * p < 0.05 compared to LPS treatment alone.
Figure 4Effects of CTB on transcription factor translocation. RAW264.7 cells co-transfected with plasmids containing AP-1-luc (A) or NF-κB (B) luciferase constructs were treated with CTB in the presence or absence of LPS. Luciferase activity was determined by luminometry. Values are the mean ± SD of triplicate experiments. * p < 0.05 compared to LPS treatment alone; # p < 0.05 compared to control group.
Figure 5Effects of CTB on the upstream pathway of activator protein (AP)-1. RAW264.7 cells were pre-treated with 50 µM CTB for 30 min and then stimulated with 1 µg/mL LPS for the indicated time. After immunoblotting, the levels of phospho- or total forms of ERK, JNK and p38 were identified based on their antibodies (A); RAW264.7 cells were pre-treated with 10 µM p38 MAPK inhibitor (SB203580) for 30 min before treatment with 1 µg/mL LPS for 6 h. mRNA expression of iNOS, COX-2, and TNF-α was measured by real-time PCR (B); RAW264.7 cells co-transfected with plasmids containing AP-1-luc luciferase construct were treated with CTB in the presence or absence of LPS (C); Values are the mean ± SD of triplicate experiments. * p < 0.05 compared to LPS treatment alone; # p < 0.05 compared to control group. RAW264.7 cells were pre-treated with different concentrations of SB203580 for 30 min and then stimulated with 1 µg/mL LPS for 1 h. Cell lysates were immunoblotted with phospho- or total MKK3/6 (D); Superposition of the crystal structures of MKK3 and MKK6 with the docking structure of the CTB (E). A typical experiment of three independent experiments is shown.
Primer sequences and conditions for RT-PCR.
| Gene Name | GenBank Accession Number | Primer Sequence (5′–3′) |
|---|---|---|
| NM_001289726 | F: CACTCACGGCAAATTCAACGGCA | |
| R: GACTCCACGACATACTCAGCAC | ||
| NM_001313921 | F: CCCTTCCGAAGTTTCTGGCAGCAG | |
| R: GGCTGTCAGAGCCTCGTGGCTTTGG | ||
| NM_011198 | F: CACTACATCCTGACCCACTT | |
| R: ATGCTCCTGCTTGAGTATGT | ||
| NM_013693.3 | F: TGCCTATGTCTCAGCCTCTTC | |
| R: GAGGCCATTTGGGAACTTCT | ||
| NM_008361 | F: TGAAGCAGCTATGGCAACTG | |
| R: AGGTCAAAGGTTTGGAAGGA |
F: forward primer; R: reverse primer.